Alpine Immune Sciences, Inc. focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an ICOS/CD28 antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202 program for the treatment of cancer. The company has a collaboration and licensing agreement with the Kite Pharma, Inc. for discovering and developing protein-based immunotherapies targeting the immune synapse to treat cancer. Alpine Immune Sciences, Inc. is headquartered in Seattle, Washington.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone206-788-4545
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$700,000.00
Profitability
Miscellaneous
Employees48
Next Earnings Date5/13/2019 (Estimated)
OptionableNot Optionable
Alpine Immune Sciences (NASDAQ:ALPN) Frequently Asked Questions
What is Alpine Immune Sciences' stock symbol?
Alpine Immune Sciences trades on the NASDAQ under the ticker symbol "ALPN."
How were Alpine Immune Sciences' earnings last quarter?
Alpine Immune Sciences Inc (NASDAQ:ALPN) released its earnings results on Monday, March, 18th. The biotechnology company reported ($0.80) earnings per share (EPS) for the quarter, meeting the Zacks' consensus estimate of ($0.80). View Alpine Immune Sciences' Earnings History.
When is Alpine Immune Sciences' next earnings date?
What price target have analysts set for ALPN?
5 analysts have issued twelve-month target prices for Alpine Immune Sciences' shares. Their forecasts range from $12.00 to $13.00. On average, they expect Alpine Immune Sciences' stock price to reach $12.80 in the next twelve months. This suggests a possible upside of 89.6% from the stock's current price. View Analyst Price Targets for Alpine Immune Sciences.
What is the consensus analysts' recommendation for Alpine Immune Sciences?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alpine Immune Sciences in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Alpine Immune Sciences.
Has Alpine Immune Sciences been receiving favorable news coverage?
Press coverage about ALPN stock has trended positive this week, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Alpine Immune Sciences earned a media sentiment score of 2.7 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term.
Who are some of Alpine Immune Sciences' key competitors?
Some companies that are related to Alpine Immune Sciences include Assembly Biosciences (ASMB), MediciNova (MNOV), Flexion Therapeutics (FLXN), Aptorum Group (APM), Albireo Pharma (ALBO), Abeona Therapeutics (ABEO), Innate Pharma (IPHYF), Rigel Pharmaceuticals (RIGL), Kezar Life Sciences (KZR), Sinovac Biotech (SVA), Akorn (AKRX), Beyondspring (BYSI), Geron (GERN), ImmunoGen (IMGN) and Savara (SVRA).
What other stocks do shareholders of Alpine Immune Sciences own?
Who are Alpine Immune Sciences' key executives?
Alpine Immune Sciences' management team includes the folowing people:
- Dr. Mitchell H. Gold, Exec. Chairman & CEO (Age 51)
- Dr. Stanford Peng, Exec. VP of R&D and Chief Medical Officer (Age 48)
- Dr. Mark J. Litton, Pres & COO (Age 51)
- Mr. Paul Rickey, Sr. VP & CFO (Age 40)
- Dr. Kristine Swiderek Ph.D., Sr. VP of Research
How do I buy shares of Alpine Immune Sciences?
Shares of ALPN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Alpine Immune Sciences' stock price today?
One share of ALPN stock can currently be purchased for approximately $6.75.
How big of a company is Alpine Immune Sciences?
Alpine Immune Sciences has a market capitalization of $93.51 million and generates $700,000.00 in revenue each year. The biotechnology company earns $-36,490,000.00 in net income (profit) each year or ($2.63) on an earnings per share basis. Alpine Immune Sciences employs 48 workers across the globe.
What is Alpine Immune Sciences' official website?
How can I contact Alpine Immune Sciences?
Alpine Immune Sciences' mailing address is 201 Elliott Avenue West Suite 230, Seattle WA, 98119. The biotechnology company can be reached via phone at 206-788-4545 or via email at [email protected]
MarketBeat Community Rating for Alpine Immune Sciences (NASDAQ ALPN)
MarketBeat's community ratings are surveys of what our community members think about Alpine Immune Sciences and other stocks. Vote "Outperform" if you believe ALPN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALPN will underperform the S&P 500 over the long term. You may vote once every thirty days.
